Related Experiment Video

Updated: Jul 18, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Diuretics and digitalis in the treatment of chronic heart failure

S H Taylor, L Storstein

    European Heart Journal
    |January 1, 1983
    PubMed

    Insights

    Evaluating long-term heart failure treatments is complex due to varied causes, unpredictable progression, and differing drug responses. Clinical trials face challenges because chronic heart failure is terminal, limiting study durations.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Clinical Trials

    Background:

    • Chronic heart failure (CHF) presents diverse histopathological profiles based on etiology.
    • CHF progression and hemodynamic derangement severity correlate poorly with patient symptoms.
    • Myocardial drug metabolism and response in CHF patients differ significantly from healthy subjects.

    Purpose of the Study:

    • To evaluate the long-term clinical efficacy of diuretics and digitalis in treating chronic heart failure.
    • To address the complexities inherent in assessing long-term CHF interventions.

    Main Methods:

    • The abstract does not specify methods but discusses the challenges in evaluating long-term treatment efficacy.
    • Focuses on biological, clinical, and technical problems complicating evaluation.

    Main Results:

    • The abstract does not present specific results but highlights the difficulties in obtaining them.
    • Emphasizes that trial durations are limited by the terminal nature of CHF.

    Conclusions:

    • Long-term treatment evaluation for CHF is inherently complex.
    • The efficacy of treatments like diuretics and digitalis must be assessed against this challenging biological backdrop.

    More Related Videos

    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

    Published on: February 18, 2022

    A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models07:49

    A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

    Published on: July 21, 2023

    Related Concept Videos

    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.